Colossal Biosciences’ potential $20B–$30B funding round would mark one of the largest biotech valuations to date
Executive summary: Colossal Biosciences is in talks to raise new capital that would value the company between $20 billion and $30 billion. Such a valuation would represent a significant step up from its prior level, signaling strong market confidence in de‑extinction and synthetic‑biology technologies and potentially unlocking large‑scale funding for ambitious projects.
Who is involved: Colossal Biosciences’ executive team and unnamed prospective investors.
Likely next: If negotiations conclude, a funding round could close within the next few months, after which the company may disclose the final valuation and outline how the proceeds will be allocated to research and field trials.
The de‑extinction startup is reportedly negotiating new capital that could double or triple its previous valuation, according to a TechCrunch report. If the talks succeed, the infusion would provide substantial resources for advancing its genetic‑engineering projects, such as efforts to revive the woolly mammoth. The move reflects growing investor appetite for high‑risk, high‑reward synthetic‑biology ventures, though it also raises questions about regulatory scrutiny and technical feasibility.
Timeline
- — Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation (TechCrunch)
Analysis — what this means
Likely next events
- Colossal Biosciences expects to finalize the capital raise by Q4 2026.
- A successful round could bring in $2 billion–$5 billion of new capital.
- The company may announce specific de‑extinction milestones, such as embryo implantation, by mid‑2027.
Sectors affected
- De‑extinction biotechnology
- Synthetic biology
- Genetic engineering
Regulatory implications
- U.S. FDA may require pre‑market review for genetically edited organisms intended for environmental release.
- EU’s GMO directive could impose traceability, labeling, and monitoring requirements on revived species.
Historical parallels
- Ginkgo Bioworks raised approximately $1.6 billion in 2021 at a valuation near $15 billion.
- Revive & Restore secured around $50 million in funding in 2018 for its passenger‑pigeon de‑extinction effort.